18.95
+3.67%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Arcus Biosciences
From its filings with the US Securities and Exchange Commission
Arcus Biosciences is based in Hayward, California and is incorporated in Delaware. Its shares trade on NYSE under the ticker RCUS. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $247.0m and a net loss of $353.0m. At that date it held total assets of $1.14bn and shareholders' equity of $631.0m.
We are a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Our most advanced molecules are in Phase 3 registrational studies for various cancer indications and we expect our next wave of clinical-stage molecules to come from our inflammation and autoimmune disease programs. Our vision is to leverage our internal small-molecule discovery capabilities to create, develop and commercialize highly differentiated therapies that can have a meaningful impact on patients.
Casdatifan is our oral, small-molecule inhibitor of HIF-2α, a target that has been commercially validated by the approval of Merck & Co., Inc's ("Merck") HIF-2α inhibitor belzutifan. HIF-2α is a protein that is involved in sensing oxygen availability in multiple organs. In certain tumors, particularly clear cell renal cell carcinoma ("ccRCC"), HIF-2⍺ activity is highly dysregulated as a result of genetic abnormalities. This creates a situation of pseudohypoxia and the abnormal increase in HIF-2⍺-mediated expression of a wide array of proteins involved in cancer cell proliferation, survival, treatment resistance and angiogenesis.
Quoted from its 10-K, filed 25 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 15 Mar 2018
- Employees
- 601
- Website
- arcusbio.com ↗
- Head office
- 3928 POINT EDEN WAY, HAYWARD, CA, 94545
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Dr. Terry RosenChairman of the Board, Chief Executive Officer, Co-Founder, since 2015$7.3m
- Dr. Juan JaenPresident, Co-Founder, since 2015$3.3m
- Mr. Robert GoeltzChief Financial Officer$2.0m
- Ms. Jennifer JarrettChief Operating Officer$3.3m
- Ms. Carolyn TangGeneral Counsel$2.9m
- Mr. Richard MarkusChief Medical Officer
- Dr. Yasunori KanekoLead Independent Director$498,072
- Dr. Dietmar BergerDirector
- Dr. Linda HigginsDirector
- Ms. Johanna MercierDirector
- Ms. Kathryn FalbergIndependent Director$474,609
- Dr. David LaceyIndependent Director$511,540
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 36
- Environment
- 37
- Social
- 51
- Governance
- 20
- Women in the workforce
- 56%
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Arcus Biosciences Inc possesses several strengths that contribute to its competitive advantage:
Weaknesses
- Despite its strengths, Arcus Biosciences Inc also has certain weaknesses that pose challenges:
Opportunities
- Arcus Biosciences Inc can leverage various opportunities in the market to further expand and succeed:
Threats
- Arcus Biosciences Inc faces several threats that may impact its business and growth:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.